Morgan Stanley has released a research report indicating a reduction in the target price for Weigao Group (01066).
The investment bank has lowered its revenue forecasts for the company from 2026 to 2028 by 1% to 2%, reflecting persistent headwinds in the conventional consumables business from volume-based procurement (VBP) and competition, as well as the recent policy impact on the orthopedics segment. Morgan Stanley now expects overall revenue growth to be only in the low single digits.
Consequently, the bank has cut its earnings per share (EPS) estimates for Weigao Group for the 2026, 2027, and 2028 fiscal years by 11.8%, 12.6%, and 13.5%, respectively. The target price has been reduced from HK$5.2 to HK$4.5, while the "Market Perform" rating is maintained.
Comments